31 (77.5%) and 19 pts (47.5%) received ≥ 2 and 3 prior lines of therapy, respectively. ResultsĪs of July 17, 2019, 40 pts with NSCLC (22 female, median age: 68.0 years ) were enrolled. KRAS p.G12C mutant allele frequency (MAF) and PD-L1 level were examined. Primary endpoint is safety key secondary endpoints include objective response rate (ORR), disease control rate (DCR), duration of response (DOR), and progression-free survival (PFS). Key eligibility criteria include KRAS p.G12C mutation and prior systemic anticancer treatment (tx). Here, we present durability of clinical benefit and biomarker data in pts with NSCLC. The phase 1 trial of sotorasib, a KRAS G12C inhibitor, demonstrated a favorable safety profile and preliminary antitumor activity in pts with advanced solid tumors harboring KRAS p.G12C.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |